ANAPLASTIC LYMPHOMA KINASE: SIGNAL TRANSDUCTION AND THERAPEUTIC VOYAGE OF ALK INHIBITORS

• Author(s):

  Shubham jogdande | Mascarenhas Maxwell | Santosh Waghmare | Ashwini Andhale | Dr. H.V Kamble

• Keywords:

  ALK, NSCLC, ALCL, ALK Inhibitors, Crizotinib.

• Abstract:

  The Identification Of Anaplastic Lymphoma Kinase (ALK) Rearrangements In 2-5% Of Non-small Cell Lung Cancer (NSCLC) Patients Led To The Rapid Clinical Development Of Tyrosine Kinase Inhibitors. Anaplastic Lymphoma Kinase (ALK), A Tyrosine Kinase Has Attra

---

Other Details

• Paper id:

  IJSARTV7I1150773

• Published in:

  Volume: 7 Issue: 11 November 2021

• Publication Date:

  2021-11-10

Download Article